Sinopharm Tech Holdings Limited Overview
Sinopharm Tech Holdings is a Hong Kong-headquartered, Cayman-incorporated GEM micro-cap whose only revenue-generating activity is a healthcare-product and pharmaceutical "supply chain services" business — in substance, principal-basis trading of Chinese patent medicines, therapeutic drugs and health products to a highly concentrated set of customers in Hong Kong and Mainland China, conducted partly through a 51%-owned Jiangxi distribution subsidiary. Two legacy segments ("Internet+" solutions and personal protective equipment) are dormant and generated no revenue in FY2025 or FY2026. Management frames the group as an "AI-empowered big-health" platform aligned with Hong Kong's AI+ industrial policy, but no AI revenue, R&D spend or product has been disclosed. The group is balance-sheet distressed — net liabilities of HKD 48.9m, a going-concern material uncertainty, and dependence on its controlling shareholder for liquidity — and since January 2026 has been in breach of the GEM 25% public float requirement. It should be analysed as a restructured shell-like trading business rather than a technology or pharma operator.
Company's own description (Annual Report FY2026, MD&A)
Management states that during FY2026 the group adhered to its core strategy of "technology empowering health" (科技賦能健康), supported by two core businesses — the "big health industry" (大健康產業) and pharmaceutical supply chain services — while using artificial intelligence and big-data technology to accelerate digital transformation. It describes an "AI-driven operating framework" used to assess customer demand, sales trends and inventory, enabling precise procurement and flexible inventory adjustment, and claims to provide customers with efficient, tailored one-stop solutions based on accumulated procurement and supply chain know-how. Through subsidiaries it distributes pharmaceutical and healthcare products in Mainland China.
For FY2026, management acknowledged that supply chain revenue declined significantly owing to changes in the market environment, intensified industry competition and weaker purchasing power, with Mainland retail end-demand recovering more slowly than expected; it responded by optimising the product mix, strengthening negotiation with core brand owners and adjusting regional inventory allocation.
The Directors' Report states the Company's principal activity is investment holding. Note 6 defines three operating segments: (a) "Internet+" solution services; (b) supply chain services — supply chain management, data analysis and related services, trading of related goods, and trading of medical and related products; and (c) manufacturing and distribution of PPE.
Independent characterisation
Stripped of the AI and "big health" framing, the evidence in the FY2026 financial statements describes a small principal-basis wholesale trading operation:
-
100% of FY2026 and FY2025 revenue is "trading of goods" recognised at a point in time (Note 7). There is no service, subscription, licensing or data-analytics revenue line despite the segment's descriptive name.
-
The group judges itself principal, not agent: it controls goods before transfer, bears inventory risk and has pricing discretion (Note 5). Revenue is therefore recognised gross, which inflates revenue relative to economic value-add.
Gross margin is thin and volatile: (12–14% in FY2022–FY2024 and FY2026; an outlier 23% in FY2025).
Concentration is extreme: five customers accounted for 74.51% of FY2026 sales; five suppliers accounted for ~100% of purchases, the largest 67%; the group bought from only four suppliers in FY2026 (two HK, two PRC) versus nine in FY2025.
Inventory collapsed: from HKD 13.5m (30 Jun 2025) to HKD 0.1m (30 Jun 2026), consistent with back-to-back or order-driven trading rather than stocked distribution.
- There is no disclosed R&D, no capitalised software, no patents and no technology revenue.
Revenue model mix
| Revenue type (FY2026) | Share of revenue | Comment |
|---|---|---|
| Product trading (supply chain services segment) | 100% | Point-in-time, principal basis |
| Services (Internet+ solutions) | 0% | Segment dormant since at least FY2024 |
| Manufacturing (PPE) | 0% | Suspended; operating subsidiary disposed April 2025 |
| Subscription / licensing | 0% | None disclosed |
Value-chain position, customers and end-markets
The group sits in the middle of the pharmaceutical/health-product distribution chain: it buys finished Chinese patent medicines, therapeutic drugs and health products from a handful of brand owners/suppliers and resells to trade customers (distributors and retail customers) in Hong Kong and the PRC. Credit terms granted are 30–90 days (up to 180 days for certain customers); supplier credit terms are 30–60 days, although 99% of trade payables at 30 June 2026 (HKD 9.1m of 9.2m) were over one year old, indicating stretched or disputed supplier balances. End-markets are PRC retail pharmacy/consumer health and Hong Kong trade; FY2026 revenue was 57.5% Hong Kong and 42.5% PRC by customer location.
Strategy
Stated strategic themes (Annual Report FY2026)
-
"Technology empowering health" as the core strategy, anchored by big-health and pharmaceutical supply chain services.
-
Deeper AI integration into market-trend forecasting, intelligent supply chain management, customer-demand insight and process optimisation.
-
Regulatory agility in PRC drug distribution: tracking regulation, compliance risk assessments, business stress tests, closer engagement with industry associations and regulators.
-
Policy alignment with Hong Kong's AI agenda: management cites the HKSAR 2026–27 Budget naming AI a core driver of high-quality development and creating an "AI+ and Industry Development" promotion mechanism; the group positions itself as combining pharma supply chain capability with technological innovation.
-
New AI+ growth paths under evaluation: digital health platform services, smart logistics solutions, health-tech product R&D, and AI × biotechnology cross-applications, with a "regular progress-evaluation mechanism", stage gates and decision thresholds.
-
Structural optimisation and talent integration to control administrative and operating costs.
Initiatives in the last 24 months
| Initiative | Date | Detail | Measurable target |
|---|---|---|---|
| Capital reorganisation + loan capitalisation | Approved 8 Aug 2024; completed 15 Nov 2024 | Eliminated ~HKD 193m of debt; issued 450m shares and 1,480m CPS at HKD 0.1 | Completed |
| Exit from non-core segments | Feb 2025 – May 2026 | Disposal of Internet+ subsidiary (Feb 2025), PPE subsidiary (Apr 2025), 19.05% Ever Development stake (Jun 2025), two dormant HK subsidiaries (May 2026) | Completed |
| AI-driven supply chain analytics | Described FY2025–FY2026 | Data tools for procurement, inventory and demand analysis | None disclosed; no capex or R&D spend disclosed |
| M&A governance reform | Proposed FY2026 | Protective deal terms (escrow, deferred payment, asset pledges) and monitoring mechanisms for future acquisitions | Policy only |
| Internal-control upgrade on disposals | From Dec 2024 | Checklist, board approval, pre-audit copies of records before hand-over, auditor consultation | Response to FY2024 qualified opinion |
| Comprehensive internal-control review | Expected by end-2026 | Stated in FY2026 CG report | Pending |
| Recovery of Hero Global compensation | Demand 24 Aug 2026; legal letter 9 Sep 2026 | Pursuit of HKD 75.6m outstanding | Possible litigation |
Guidance and medium-term targets
No financial guidance, revenue targets, margin targets or capital-allocation targets are published. As at the FY2026 report date the directors had no plans for material investments or capital assets and no capital commitments. ESG targets are limited to holding emissions, waste density and electricity intensity at or below FY2020 baseline levels.
Products & Services
The group discloses no named brands, SKUs, platforms, pricing schedules or launch dates. The catalogue below is therefore built from segment descriptions and is complete to the extent disclosed.
Sources: Annual Report FY2026 (MD&A, Note 6, Note 7); Annual Report FY2025 (Directors' Report on Hero Global activities).
The company's ESG report adds that before launching any new product it requires samples from suppliers or factories and engages third-party professionals for quality-control checks, and that a dissatisfied customer may be offered a replacement "combination" (組合) of products — suggesting some sales are packaged product bundles.
Product Portfolio
| Segment | Offering | Description / capabilities (as disclosed) | Target customer | Launch / latest | Pricing model | Flagship named offering |
|---|---|---|---|---|---|---|
Supply chain services | Trading of Chinese patent medicines and therapeutic drugs | Procurement from brand owners and resale; regional inventory allocation across PRC provinces | PRC distributors and retail pharmacy customers | — | Per-transaction sales contract, credit 30–90 days | — |
Supply chain services | Trading of health / "big health" products | Health products sourced from a concentrated supplier base | HK and PRC trade customers | — | Per-transaction | — |
Supply chain services | "Supply chain management, data analysis and related services" | Described as AI-driven demand, sales-trend and inventory analysis embedded in trading | Same customers (bundled) | AI integration described from FY2025 | No separate revenue recognised | — |
Internet+ solution services | Internet-related solutions (legacy Hero Global: consulting, blockchain, big data, e-commerce payment/membership/precision marketing tools) | Dormant | Previously PRC online platforms and Sino-TCM | Acquired 2019; suspended | — | — |
PPE | Manufacture and distribution of PPE and consumables | Suspended after COVID demand normalised | — | c.2020; suspended | — | — |
Planned (not launched) | Digital health platform services; smart logistics solutions; health-tech product R&D; AI × biotech applications | Stated as exploration paths with stage-gate evaluation | Not specified | Not launched | — | — |
“—” = not publicly disclosed.
Financial Narrative
All figures HKD millions, fiscal years ended 30 June. Primary source: Five-Year Financial Summary and consolidated statements, Annual Report FY2026; attributable net income FY2022–FY2024 and FY2022–FY2024 balance-sheet line items from S&P Global data via StockAnalysis (secondary). Derived metrics computed by the analyst.
Per-share data
Data-quality flag. The FY2026 accounts use the same weighted-average share count (464.789m) as FY2025, even though 633.69m ordinary shares were in issue throughout FY2026 (the 450m loan-capitalisation shares were issued 15 Nov 2024). On 633.69m shares, FY2026 basic loss per share would be ≈ −1.44 HK cents. No dividend was declared in FY2024, FY2025 or FY2026; the company has had no distributable reserves in the period reviewed.
Margins and growth
Revenue CAGR FY2022–FY2026: ≈ 2.7% per year (HKD 41.0m → 45.6m), effectively flat across the cycle, with the FY2025 surge fully reversed in FY2026.
Half-year phasing (derived)
H1 FY2026 per interim results (26 Feb 2026: revenue HKD 26.769m, +41.65% YoY; attributable loss HKD 3.681m, narrowed 33.23%); other halves derived. H2 FY2025 "profit" reflects one-off gains on subsidiary disposals (HKD 6.9m) and loan capitalisation (HKD 3.9m).
The phasing shows a sharp deterioration in the second half of FY2026: revenue fell to HKD 18.8m against HKD 42.4m in the prior-year second half, with no offsetting one-off gains.
Balance sheet
FY2022–FY2024 working-capital line items: S&P via StockAnalysis. Goodwill (HKD 12.3m at FY2021) was fully impaired by FY2022; MD&A FY2025 confirms goodwill and intangibles remain fully impaired.
Debt and liquidity
Source: Annual Report FY2026 Note 36 (reconciliation of financing liabilities); MD&A FY2025/FY2026. FY2024 net current liabilities derived from MD&A current assets HKD 38.1m and current liabilities HKD 249.4m. FY2024 short-term classification reflects that all debt was overdue/on demand.
Gearing inconsistency. The company defines gearing as interest-bearing borrowings ÷ total assets. On that definition, FY2026 shareholder loans alone (HKD 22.4m) equal ~100% of total assets, and including the CPS liability ~237%. The reported 75.8% cannot be reconciled to disclosed balances; the reported FY2025 figure of 9% likewise appears to exclude shareholder loans and the CPS liability.
Cash flow
FY2025–FY2026 from Annual Report FY2026 cash flow statement; FY2022–FY2024 from S&P via StockAnalysis; FY2024 shareholder advances = Quantum drawdowns of HKD 10m (8 Nov 2023) and HKD 5m (1 Feb 2024).
FY2026 operating cash outflow (HKD 4.0m) was cushioned by a HKD 3.1m working-capital release — inventory down HKD 13.4m and receivables down HKD 12.6m, offset by a HKD 22.8m reduction in payables and accruals. Before working capital, operations consumed HKD 6.9m. The group repaid the bank loan (HKD 3.3m) and the residual Creative Big borrowing (HKD 1.6m), funded by HKD 8.0m of new Quantum advances at 5%.
Ratios
Not meaningful: ROE and debt/equity (negative equity throughout FY2022–FY2026); ROIC (negative invested capital); net debt/EBITDA in FY2022, FY2023 and FY2026 (negative EBITDA). Net debt/EBITDA was ≈ 39.4x in FY2024 and ≈ 6.5x in FY2025.
Commentary on trends, inflections and drivers
Revenue. Revenue was stuck at HKD 41–43m in FY2022–FY2024, surged 48% in FY2025 on what management called higher demand for healthcare products and improved supply chain efficiency, and fell back 26% in FY2026 amid weak PRC retail demand and price competition. The PRC subsidiary's revenue more than halved (HKD 42.9m → 19.4m), while Hong Kong revenue rose 43% (HKD 18.4m → 26.2m). Revenue therefore depends on a few customer relationships, and swings by tens of percent with the loss or gain of a single account (Customer D and Customer E, each ~HKD 6.7m in FY2025, did not appear above the 10% threshold in FY2026, while Customer C at HKD 12.4m appeared).
Earnings quality. In every year from FY2022 to FY2025 the reported bottom line was dominated by non-operating items: large "other income and gains" (HKD 39.4m, 106.8m, 18.1m, 10.8m) largely from disposals, profit-guarantee compensation and debt-restructuring gains; and large impairments (HKD 58.6m in FY2022, 74.8m in FY2023, chiefly the Hero Global compensation receivable). FY2026 is the first "clean" year with few one-offs (other income HKD 1.4m, mainly the write-back of stale payables and contract liabilities), and it shows the underlying run-rate: a core operating loss of ~HKD 8m on ~HKD 46m of revenue.
Cost base. Administrative expenses have been cut by 76% in four years (HKD 41.4m → 9.9m) and headcount is down to 31. The FY2026 tripling of selling and distribution costs while revenue fell is unexplained in the filings and is the main driver of the core-loss widening.
Balance sheet inflection. The November 2024 loan capitalisation was the decisive event: total liabilities fell from HKD 250m to HKD 88m and the deficit from HKD 206m to HKD 37m. However, the deficit widened again to HKD 48.9m in FY2026 as losses resumed, and the CPS created a new liability component (HKD 30.7m) carrying 5% preferred distributions (HKD 7.4m per year for five years), which the company has deferred.
Liquidity. Cash of HKD 5.6m against current liabilities of HKD 55.4m; operating cash burn of ~HKD 4–6m per year; survival depends on the controlling shareholder's undertaking (dated 17 Aug 2026) not to demand repayment for 18 months, and on discretion to defer CPS distributions for up to 10 years.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Status |
|---|---|---|
"Internet+" solution services | Internet-related solution services; legacy of Hero Global (business management/consulting re "Internet Plus", blockchain, big data, e-commerce technology) | Dormant; no revenue FY2024–FY2026; principal subsidiary Sinopharm Health Cross-border E-Commerce disposed Feb 2025 |
Supply chain services | Supply chain management, data analysis and related services; trading of related goods; trading of medical and related products | Sole revenue source |
Manufacturing & distribution of PPE | Manufacture and sale of PPE, consumables and related goods (COVID-era) | Suspended; Sinopharm (Hong Kong) Industrial disposed Apr 2025 |
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Supply chain services | 41.3 | 61.253 | 45.582 |
Internet+ solution services | 0 | 0 | 0 |
PPE manufacturing & distribution | 0 | 0 | 0 |
Total revenue | 41.277 | 61.253 | 45.582 |
Revenue by Segment
| Segment result (HKD Mn) | FY2025 | FY2026 |
|---|---|---|
Supply chain services | -0.931 | -5.950 |
Internet+ solution services | -0.004 | 0.022 |
PPE manufacturing & distribution | -0.797 | -0.015 |
Total segment loss | -1.732 | -5.943 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Supply chain revenue YoY growth (%) | — | 48.4 | -25.6 |
Supply chain gross margin (%) | 12 | 23 | 14 |
Supply chain segment result margin (%) | — | -1.5 | -13.1 |
Supply chain share of group revenue (%) | 100 | 100 | 100 |
Group Entities
| Entity | Place of incorporation / operation | Paid-up capital | Group interest | Activity |
|---|---|---|---|---|
China Success Enterprises Limited | BVI / Hong Kong | USD 2,000 | 100% (direct) | Investment holding |
Sinopharm Tech Corporate Management Limited (國藥科技企業管理有限公司; formerly China Vanguard Corporate Management Ltd) | Hong Kong | HKD 20,000,000 | 100% (direct) | Investment holding; purchaser under Hero Global SPA |
弘名有限公司 (English name not stated in Chinese report) | Hong Kong | HKD 1 | 100% (indirect) | Distribution of PPE |
天渝有限公司 ("Tianyu") | BVI / Hong Kong | USD 100 | 57% (indirect) | Investment holding |
江西鷺嶼 ("Jiangxi Luyu") | PRC (limited liability) | RMB 10,000,000 | 51% (indirect) | Distribution of medical products |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 40.985 | 42.839 | 41.277 | 61.253 | 45.582 |
Cost of sales (HKD Mn) | 35.053 | 37.369 | 36.258 | 47.022 | 39.161 |
Gross profit (HKD Mn) | 5.932 | 5.470 | 5.019 | 14.231 | 6.421 |
Other income and gains (HKD Mn) | 39.350 | 106.849 | 18.085 | 10.843 | 1.366 |
Impairment losses on receivables and other assets, net (HKD Mn) | 58.554 | 74.782 | 2.587 | 8.426 | 0.883 |
Selling and distribution expenses (HKD Mn) | 1.003 | 2.251 | 0.495 | 1.648 | 4.685 |
Administrative and operating expenses (HKD Mn) | 41.431 | 19.775 | 13.687 | 11.285 | 9.902 |
Core operating result: GP less S&D and admin (HKD Mn) | -36.502 | -16.556 | -9.163 | 1.298 | -8.166 |
EBIT: pre-tax loss plus finance costs (HKD Mn) | -77.748 | -2.836 | 3.601 | 4.775 | -7.683 |
Depreciation and amortisation (HKD Mn) | 2.400 | 2.010 | 1.380 | 1.333 | 1.228 |
EBITDA (HKD Mn) | -75.348 | -0.826 | 4.981 | 6.108 | -6.455 |
Finance costs (HKD Mn) | 16.410 | 8.571 | 23.933 | 5.854 | 4.007 |
Loss before tax (HKD Mn) | -94.158 | -11.407 | -20.332 | -1.079 | -11.690 |
Income tax (charge)/credit (HKD Mn) | 0.387 | 1.307 | -0.083 | -0.291 | -0.213 |
Loss for the year (HKD Mn) | -93.771 | -10.100 | -20.415 | -1.370 | -11.903 |
Loss attributable to owners (HKD Mn) | -88.000 | -10.640 | -19.700 | -0.867 | -9.142 |
Per-Share Data and Share Count (millions)
| Metric | FY2025 | FY2026 |
|---|---|---|
Basic and diluted loss per share (HK cents) | -0.19 | -1.97 |
Weighted average ordinary shares used (millions) | 464.789 | 464.789 |
Dividends per share (HK cents) | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | — | 4.52 | -3.65 | 48.39 | -25.58 |
Gross margin (%) | 14.47 | 12.77 | 12.16 | 23.23 | 14.09 |
Core operating margin (%) | -89.06 | -38.65 | -22.20 | 2.12 | -17.92 |
EBIT margin (%) | -189.70 | -6.62 | 8.72 | 7.80 | -16.86 |
EBITDA margin (%) | -183.84 | -1.93 | 12.07 | 9.97 | -14.16 |
Net margin, attributable (%) | -214.71 | -24.84 | -47.73 | -1.42 | -20.06 |
Income Statement (Half-Yearly)
| Metric (HKD Mn) | H1 FY2025 | H2 FY2025 | H1 FY2026 | H2 FY2026 |
|---|---|---|---|---|
Revenue | 18.898 | 42.355 | 26.769 | 18.813 |
Loss attributable to owners | -5.513 | 4.646 | -3.681 | -5.461 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 76.886 | 33.482 | 44.490 | 51.736 | 22.439 |
Total liabilities (HKD Mn) | 250.283 | 213.236 | 250.089 | 88.430 | 71.319 |
Net liabilities / total deficit (HKD Mn) | -173.397 | -179.754 | -205.599 | -36.694 | -48.880 |
Capital deficiency attributable to owners (HKD Mn) | -166.777 | -172.733 | -199.480 | -36.868 | -46.404 |
Non-controlling interests (HKD Mn) | -6.620 | -7.021 | -6.119 | 0.174 | -2.476 |
Cash and bank balances (HKD Mn) | 2.99 | 1.78 | 2.64 | 6.946 | 5.617 |
Trade receivables, net (HKD Mn) | 28.42 | 8.10 | 20.03 | 18.125 | 5.715 |
Inventories (HKD Mn) | 1.35 | 0.86 | 3.54 | 13.481 | 0.118 |
Total current assets (HKD Mn) | 48.08 | 27.05 | 38.07 | 49.133 | 20.965 |
Property, plant and equipment (HKD Mn) | 4.65 | 1.16 | 3.88 | 2.075 | 1.474 |
Goodwill and intangibles (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Other borrowings incl. Creative Big (HKD Mn) | 71.933 | 1.557 | 0 |
Bank borrowings (HKD Mn) | 0 | 3.283 | 0 |
Amounts due to shareholders (HKD Mn) | 125.490 | 13.773 | 22.367 |
CPS liability component (HKD Mn) | 0 | 27.455 | 30.731 |
Lease liabilities (HKD Mn) | 1.323 | 0.665 | 0 |
Total debt incl. CPS liability (HKD Mn) | 198.746 | 46.733 | 53.098 |
Short-term portion (HKD Mn) | 198.746 | 26.680 | 37.168 |
Long-term portion (HKD Mn) | 0 | 20.054 | 15.930 |
Net debt (HKD Mn) | 196.106 | 39.787 | 47.481 |
Net current liabilities (HKD Mn) | -211.3 | -19.243 | -34.424 |
Company-reported gearing ratio (%) | 162 | 9 | 75.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | -36.76 | 4.73 | -9.25 | -5.697 | -4.022 |
Capital expenditure (HKD Mn) | 0.12 | 0 | 3.33 | 0 | 0 |
Free cash flow (HKD Mn) | -36.89 | 4.73 | -12.58 | -5.697 | -4.022 |
Financing cash flow (HKD Mn) | 32.24 | -4.52 | 14.98 | 9.984 | 3.073 |
Shareholder advances received (HKD Mn) | 0 | 0 | 15.0 | 9.0 | 8.0 |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROA, attributable loss / year-end total assets (%) | -114.5 | -31.8 | -44.3 | -1.7 | -40.7 |
Asset turnover, revenue / year-end assets (x) | 0.53 | 1.28 | 0.93 | 1.18 | 2.03 |
Interest coverage, EBIT / finance costs (x) | -4.74 | -0.33 | 0.15 | 0.82 | -1.92 |
Current ratio (x) | — | — | 0.15 | 0.72 | 0.38 |
Ratio | FY2025 | FY2026 | — | — | — |
Days sales outstanding (days) | 108.0 | 45.8 | — | — | — |
Days inventory outstanding (days) | 104.6 | 1.1 | — | — | — |
Days payables outstanding (days) | 178.1 | 85.4 | — | — | — |
Cash conversion cycle (days) | 34.5 | -38.5 | — | — | — |
Region revenue (HKD Mn)
| Region revenue (HKD Mn) | FY2025 | FY2026 |
|---|---|---|
PRC (Mainland China) | 42.877 | 19.355 |
Hong Kong | 18.376 | 26.227 |
Total | 61.253 | 45.582 |
Region growth and mix (%)
| Region growth and mix (%) | FY2025 | FY2026 |
|---|---|---|
PRC share of revenue (%) | 70.0 | 42.5 |
Hong Kong share of revenue (%) | 30.0 | 57.5 |
PRC revenue growth YoY (%) | — | -54.9 |
Hong Kong revenue growth YoY (%) | — | 42.7 |
Capital Markets
| Item | Value | Source / date |
|---|---|---|
Last price | HKD 0.159 | StockAnalysis, 9 Oct 2026 |
Prior observed price | HKD 0.209 (10 Sep 2026); HKD 0.163 (29 Jul 2026) | StockAnalysis |
52-week range | HKD 0.148 – 0.355 | StockAnalysis (as of Sep 2026) |
Beta | 1.69 | StockAnalysis |
Loan-capitalisation issue price | HKD 0.10 (Nov 2024); closing price on agreement date HKD 0.123 (14 Jun 2024) | Annual Report FY2025 |
1/3/5-year total return | Not publicly disclosed in sources reviewed; series distorted by the 25:1 consolidation (29 Aug 2023) and ~HKD 0.1 dilutive issuance | — |
Typical daily volume | Very thin (e.g., 1,400 shares on 10 Sep 2026) | StockAnalysis |
Valuation Multiples
| Multiple | Basic (ordinary shares only) | Fully converted (CPS as equity) |
|---|---|---|
Market capitalisation (HKD Mn) | 100.8 | 336.1 |
Enterprise value (HKD Mn) | 148.3 (mkt cap + shareholder loans 22.4 + CPS liability 30.7 − cash 5.6) | 352.9 (mkt cap + shareholder loans 22.4 − cash 5.6) |
EV / Sales FY2026 (x) | 3.25 | 7.74 |
EV / EBITDA | n/m (negative EBITDA) | n/m |
P/E | n/m (loss) | n/m |
P/B | n/m (negative equity) | n/m |
Capital Markets (Annual)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per ordinary share (HKD) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Analyst Conclusions
Management guidance and consensus
Management offers only qualitative confidence ("full of confidence in business prospects") and an AI+ exploration agenda; no quantitative guidance. Analyst coverage: none with published estimates (Simply Wall St records zero analysts submitting estimates); consensus growth expectations are not available.
Bull case
-
Hero Global recovery is a step-change asset. The HKD 75.6m outstanding compensation exceeds the group's HKD 48.9m net deficit; even partial recovery through litigation would restore positive equity — and has a carrying value of essentially nil, so any recovery is pure upside.
-
Controlling-shareholder alignment. Mr. Yam holds 74% of the votes and HKD 93m of CPS; he has funded the group repeatedly and capitalised debt at HKD 0.1. A controller with that much at stake is incentivised to inject assets or recapitalise rather than let the listing lapse.
-
Operating leverage on a tiny cost base. At FY2025-like volume (HKD 61m) and margin (23%), the HKD 14.6m combined S&D and admin cost base is roughly covered; a single new large customer could swing the core result back to break-even.
Bear case
-
Going concern rests on one person. With HKD 5.6m of cash, HKD 34.4m of net current liabilities and ~HKD 4–7m of annual operating burn, survival depends on Mr. Yam's continued support; the 18-month standstill expires around February 2028.
-
The FY2025 recovery was not durable. FY2026 revenue −26%, gross margin back to 14%, H2 revenue down 56% YoY; one-off gains masked the run-rate in FY2023–FY2025, and the clean FY2026 run-rate is a HKD 8m core loss.
-
Governance and disclosure deficits. No chair/CEO, three auditors and three company secretaries in two years, qualified opinions, a public-float breach inconsistent with earlier monthly-return confirmations, and multiple numerical errors in the FY2026 annual report raise the risk of further regulatory action, including suspension.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | Why it matters |
|---|---|---|
| Public float restoration (placing or sell-down) | Ongoing | Prolonged breach risks suspension; restoration also unlocks CPS conversion |
| AGM (rotation of Ms. Kwok and Mr. Lau; reappointment of Suya WWC) | Expected ~Dec 2026 | Board continuity |
| Q1/interim trading (six months to 31 Dec 2026) | Interim results ~Feb 2027 | Tests whether the H2 FY2026 revenue collapse persists |
| Legal action vs. Hero Global vendor | From Sep 2026 | Potential HKD 75.6m recovery |
| Comprehensive internal-control review | By end-2026 | Remediation of governance flags |
| Any asset injection, placing or CPS redemption/conversion | Unscheduled | Capital-structure reset |
| Customer concentration (Customers A and C) | Ongoing | ~57% of revenue |
| CPS distribution arrears (HKD 14.8m) | Due 31 Dec 2027 | Liquidity and dividend blocker |
Analyst verdict
Sinopharm Tech Holdings is best understood not as a healthcare-technology company but as a restructured GEM listing housing a small, loss-making, highly concentrated pharmaceutical and health-product trading operation. The November 2024 loan capitalisation was genuinely transformative — it removed ~HKD 193m of overdue convertible-bond and shareholder debt and averted the existential threat posed by the 2023 winding-up petition — yet two years on, the business has not demonstrated a self-sustaining model. FY2026 data are unambiguous: revenue fell 26% to HKD 45.6m, gross profit more than halved, the core operating loss reached ~HKD 8m, and net liabilities widened to HKD 48.9m, all without the one-off gains that flattered FY2023–FY2025.
The AI narrative is unsupported by any disclosed spending, IP or revenue, and should carry no valuation weight until the company reports a funded, measurable initiative. The governance record — no chair or CEO, frequent auditor and secretary changes, qualified opinions, an unremedied public-float breach, and visible errors in the FY2026 annual report — calls for a meaningful discount and heightened scrutiny of every reported figure.
The equity's value therefore rests on two options rather than on operations: (i) recovery of the HKD 75.6m Hero Global compensation, which is credit-impaired to nil and depends on the vendor's solvency and willingness to pay; and (ii) the controlling shareholder's intentions for the listed platform, given his 74% voting control and large CPS position. At ~HKD 148m basic EV against negative EBITDA, the market is already pricing a material probability of a corporate action.
Verdict: a speculative special situation, not an investable operating business. Monitor float restoration, the Hero Global claim, and H1 FY2027 trading; absent a recapitalisation or asset injection, the base case is continued losses and dependence on shareholder funding.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Age | Appointed | Background / education | FY2026 total emoluments (HKD K) |
|---|---|---|---|---|---|
Mr. CHIU Sin Nang Kenny (趙善能) | Executive Director; authorised representative; member, Remuneration and Nomination Committees | 64 | 2 Jun 2025 | FCPA (HK and Australia), 35+ years in financial accounting and corporate management; NED of China Changbaishan International (formerly Hua Yin International, 0989); director, Hong Kong International Family Office Ltd; former ED of Kin Shing Holdings (1630); former INED of Keyne (0009), Sincere Watch (0444), Baijin Life Science (1466), Coolpad (2369), Kingston Financial (1031). MAcc (CUHK), EMPAcc and CFO certificate (Shanghai National Accounting Institute), MCom (UNSW), LLB (Peking University), BAS and BA Econ (York University). Criticised by the HKEX Listing Committee (regulatory announcement 9 May 2023) over his tenure as Keyne INED. Beneficial owner of Creative Big Limited (547.6m CPS). | 60 |
Ms. KWOK Shuk Yi (郭淑儀) | Executive Director; authorised representative; member, Remuneration and Nomination Committees | 50 | Joined Jul 2008; ED 5 Sep 2022 | BBA (RMIT, distinction; FY2025 report states Bachelor in HR Management); council member, Guangdong AI Industry Association; "AI Enterprise Management Expert" and chair, Shenzhen AI Industry Association; 20+ years senior management; responsible for overall operations and strategy | 726 (fees 60; salary 648; pension 18) |
Mr. LAU Fai Lawrence (劉斐) | INED; Chair of Audit, Remuneration and Nomination Committees | 55 | Jan 2020 | Practising CPA (HK); BBA (HKU 1994), MCorpFin (PolyU 2007); ED of Hengxin Technology (1085) since Jul 2025; company secretary of BBMG (2009) and HM International (8416); joint company secretary of Huanxi Media (1003) since Aug 2026; INED of China Ecotourism (1371); numerous prior directorships, several at companies later delisted | 60 |
Mr. HEUNG Pik Lun (向碧倫) | INED; member of all three committees | 64 | Sep 2023 | 20+ years in PRC/HK business; former ED of Master Glory Group (275, delisted Feb 2021); Royal Chartered Surveyor; holds 3.92m ordinary shares (0.62%) | 60 |
刁志強 (English name not stated in report reviewed) | INED; member of all three committees | 66 | 19 Dec 2025 | 30+ years in AI, semiconductors, wireless and multimedia; former VP, Qualcomm (internet business development, China smartphone ecosystem); former VP Communications Technology and R&D Director, ASTRI; founder of Bitzmo Inc. (UWB semiconductors, Silicon Valley); prior roles at Cadence, National Semiconductor, TRW; adviser to HK Science Park and Bryan, Garnier & Co; BS/MS EE, Cornell | 80 |
余秉明 (English name not stated in report reviewed) | INED; member of all three committees | 65 | 19 Dec 2025 | Director of PAS Company Limited since Jun 2002; sales and marketing background; former INED of Hang Fu Holdings (0643) Aug 2022–Feb 2023 | 80 |
Governance Overview
| Attribute | Status (FY2026) |
|---|---|
Board size | 6 (2 ED, 0 NED, 4 INED) after 19 Dec 2025 |
Independence | 4 of 6 (67%) |
Chair / CEO | No chairman or CEO appointed; both roles exercised collectively by the executive directors — deviation from CG Code C.2.1 |
Committees | Audit (4 INEDs, chaired by Lau); Remuneration (6 members, chaired by Lau); Nomination (6 members, chaired by Lau since 19 Dec 2025) |
Board meetings FY2026 | 6 (FY2025: 11) |
Board evaluation | Not conducted in FY2026 (required at least biennially under CG Code B.1.4); scheduled for FY2027 |
Gender diversity | 1 female director of 6; workforce 58% male / 42% female |
Service contracts | None; directors subject to rotation |
Major Shareholders
| Holder | Ordinary shares | % of ordinary | CPS (non-voting) | CPS as % of ordinary | Ultimate owner |
|---|---|---|---|---|---|
Integrated Asset Management (Asia) Ltd ("IAM") and concert parties | 321,694,520 | 50.77 | 932,541,460 | 147.16 | Mr. YAM Tak Cheung (任德章) |
Quantum Worldwide Investment Ltd | 150,000,000 | 23.67 | 0 | 0 | Mr. YAM Tak Cheung |
Creative Big Limited | 0 | 0 | 547,609,590 | 86.42 | Mr. CHIU Sin Nang Kenny (ED) |
Mr. HEUNG Pik Lun (INED) | 3,920,000 | 0.62 | 0 | 0 | — |
Ms. KWOK Shuk Yi (ED) — options | 1,600,000 (options) | 0.25 | — | — | — |
Mr. LAU Fai Lawrence (INED) — options | 160,000 (options) | 0.03 | — | — | — |
Public | ≈158,078,535 | ≈24.95 | — | — | — |
Competitive Landscape
Key Competitors
| Competitor | Listing | Relevance | Scale indicator |
|---|---|---|---|
Sinopharm Group Co. Ltd. | 1099.HK | Largest PRC pharma distributor | FY2025 revenue RMB 575.2bn (−1.6%); attributable profit RMB 7.16bn |
Shanghai Pharmaceuticals Holding | 2607.HK / 601607.SS | National distributor and manufacturer | ≈USD 38bn sales (Forbes Global 2000, 2025) |
China Resources Pharmaceutical Group | 3320.HK | National distributor | ≈USD 35.8bn sales (Forbes Global 2000, 2025) |
Jointown Pharmaceutical Group | 600998.SS | Private national distributor | — |
China Traditional Chinese Medicine Holdings | 0570.HK | Sinopharm-group TCM platform; overlaps in Chinese patent medicine | — |
Sinopharm Accord | 000028.SZ | Sinopharm-group regional distribution/retail | H1 2025 revenue RMB 36.8bn |
Yixintang / LBX / Dashenlin (PRC pharmacy chains) | Shenzhen/Shanghai | Downstream buyers with direct sourcing | — |
Regional Jiangxi wholesalers (unlisted) | — | Direct local competition for Jiangxi Luyu | — |
HK health-product traders (e.g., small GEM/Main Board issuers) | Various | Competition for HK trade customers | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Sinopharm Tech (8156) FY2026 | Sinopharm Group (1099) FY2025 | Shanghai Pharma | CR Pharma |
|---|---|---|---|---|
Revenue | HKD 45.6m | RMB 575.2bn | ≈USD 38bn | ≈USD 35.8bn |
Revenue growth | −25.6% | −1.6% | — | — |
Gross margin | 14.1% | 7.2% | — | — |
Operating margin | −16.9% (EBIT) | 3.0% | — | — |
Net margin | −20.1% | 1.2% | — | — |
Employees | 31 | ≈94,910 | — | — |



